Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy by Ashrafizadeh, M. et al.
Progress in Natural Compounds/siRNA Co-delivery Employing
Nanovehicles for Cancer Therapy
Milad Ashrafizadeh, Ali Zarrabi, Kiavash Hushmandi, Farid Hashemi, Ebrahim Rahmani Moghadam,
Mehdi Raei, Mahshad Kalantari, Shima Tavakol, Reza Mohammadinejad, Masoud Najafi,*
Franklin R. Tay, and Pooyan Makvandi*
Cite This: ACS Comb. Sci. 2020, 22, 669−700 Read Online
ACCESS Metrics & More Article Recommendations
ABSTRACT: Chemotherapy using natural compounds, such as
resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin,
and camptothecin, is of importance in cancer therapy because of
the outstanding therapeutic activity and multitargeting capability of
these compounds. However, poor solubility and bioavailability of
natural compounds have limited their efficacy in cancer therapy.
To circumvent this hurdle, nanocarriers have been designed to
improve the antitumor activity of the aforementioned compounds.
Nevertheless, cancer treatment is still a challenge, demanding novel
strategies. It is well-known that a combination of natural products
and gene therapy is advantageous over monotherapy. Delivery of
multiple therapeutic agents/small interfering RNA (siRNA) as a
potent gene-editing tool in cancer therapy can maximize the
synergistic effects against tumor cells. In the present review, co-
delivery of natural compounds/siRNA using nanovehicles are
highlighted to provide a backdrop for future research.
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■ INTRODUCTION
According to the World Health Organization (WHO), 9.6
million deaths are attributed to cancer. This life-threatening
disorder was the second leading cause of death worldwide in
2018.1 Despite considerable progress in anticancer therapy,
many challenges still exist.2,3 One of the challenges is the off-
targeting feature of conventional cancer therapeutics that
significantly diminishes their therapeutic efficacy.4,5
In light of this, research scientists have focused on using
targeted delivery in overcoming cancer cells. Notably, targeted
delivery systems are able to inhibit tumor growth and reduce
tumor burden.6 It is held that designing novel nanoscale
delivery systems for delivery of siRNA can improve its efficacy
in gene silencing. It appears that resistance of cancer cells to
chemotherapy has limited the potential of targeted delivery
systems. SiRNA is a powerful tool in reversing chemoresistance
of cancer cells by down-regulation of oncogene factors, such as
Survivin, Bcl-xl, and Mcl-1.7,8 Thus, understanding the
mechanisms involved in drug resistance can help render
anticancer therapy more efficacious.9 Another issue in
anticancer therapy is the low efficacy of monotherapy in the
eradication of cancer cells.10 These difficulties have spurred
scientists toward developing co-delivery strategies for anti-
cancer therapy. Combination cancer treatment indeed has
significant appeal owing to its many advantages over
monodelivery therapeutics, including improved efficacy by
synergistic effects and overcoming drug resistance.11−13 In this
regard, various siRNA and natural compounds co-delivery
vehicles have been developed to achieve more effective therapy
than conventional monodelivery.14 Natural compounds,
because of their biobased origin, have attracted more attention
than synthetic drugs.15 The present Review aims to provide a
summary of the potential of natural compounds-siRNA co-
delivery platforms in the elimination of cancer cells and
suppression of their resistance to chemotherapy.
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■ NATURAL COMPOUNDS IN ANTICANCER
THERAPY: AN OVERVIEW
Natural compounds have opened new vistas in anticancer
therapy because of their structural and chemical diversity.15−18
These compounds are of importance in the field of drug
discovery that can lead to the discovery of novel cancer
therapeutics.19−21 More than 100 natural products and their
analogs are currently applied clinically or in clinical trials.22,23
Between 1981 and 2010, up to 50% of antitumor drugs
approved by the US Food and Drug Administration (FDA) are
natural compounds or their analogs.24 Accordingly, natural
products are important in anticancer therapy. Numerous
experiments have evaluated the efficacy of natural products in
anticancer therapy. Because of their multitargeting capability,
natural compounds can negatively affect the different aspects of
cancer cells, such as proliferation, viability, and metastasis.25−32
In this way, natural compounds target various molecular
pathways. The most common manner in which natural
products participate in anticancer therapy is stimulation of
apoptotic cell death.33 Administration of natural products
induces mitochondrial-mediated and endoplasmic reticulum
(ER)-mediated apoptosis.34,35 Natural products enhance the
production of reactive oxygen species (ROS) that stimulate
mitochondrial dysfunction, as well as ER stress.36,37 By
increasing ROS generation, the integrity of the mitochondrial
membrane is disrupted. During this process, expression of the
antiapoptotic factor Bcl-2 is down-regulated,38 while the pro-
apoptotic factor Bax is up-regulated. This causes the release of
cytochrome C (Cyt C) from the mitochondria and activation
of the caspase cascade that results in apoptosis.39 Another
pathway is the induction of ER stress-mediated apoptosis.40
Natural product supplements trigger ER stress by enhancing
ROS generation. This, in turn, causes apoptotic cell death by
upregulation of C/EBP homologous protein (CHOP).41 In
addition to apoptotic cell death, natural products are capable of
targeting molecular pathways involved in the proliferation of
cancer cells. The PI3K/Akt signaling pathway is a vital axis for
the proliferation and growth of cancer cells.42 This pathway
can be inhibited by an onco-suppressor factor known as
PTEN.43 Studies have demonstrated that natural products are
capable of activating PTEN in suppressing the PI3K/Akt
signaling pathway, thereby decreasing the proliferation and
viability of cancerous cells.44 Manu natural products that can
target molecular pathways involved in metastasis and invasion
of cancer cells.
Epithelial-to-mesenchymal transition (EMT) is a process
that causes metastasis of cancer cells via malignant trans-
formation of epithelial cells into mesenchymal cells.45,46
Natural products have shown potential in suppressing EMT
to minimize their migration and improve cancer prognosis.47
The upstream modulators of EMT can also be targeted by
natural products. It is held that Wnt and STAT3 are upstream
modulators of EMT in cancer.48,49 The administration of
natural products inhibits both Wnt and STAT3 to suprress
EMT.50,51 In addition, ZEB proteins that induce EMT during
cancer metastasis are also down-regulated by natural
products.52
Natural products are promising candidates in anticancer
therapy due to their capacity in affecting diverse targets such as
growth and migration of cancer cells as well as targeting
different molecular pathways.53−55 However, the poor
bioavailability of these valuable compounds has negative
impact on their anticancer therapeutic activity.56 The
application of nanocarriers can remarkably enhance the
antitumor potential of natural products, protect them against
degradation before reaching the tumor sites, and augment their
accumulation in cancer cells via penetrating into the blood-
tumor barrier (BTB).56−59 These benefits support the use of
nanoparticles for natural product delivery in anticancer
therapy.
■ SiRNA: BASICS, ROLE IN ANTICANCER THERAPY,
CHALLENGES, AND POSSIBLE STRATEGIES
Conventional therapeutics have drawbacks, of which the
limitation in targeting just one special molecular pathway or
protein is the most important.60,61 Consequently, attention has
been directed toward using genetic tools in anticancer
therapy.62 RNA interference (RNAi) is one of the most
powerful genetic tools used in anticancer therapy.63 Cancer
occurs as a result of mutations in onco-suppressor and
oncogene factors, leading to uncontrolled cell growth and
inhibition of apoptosis.64,65 Different driver genes accounting
for enhancing growth and malignancy of cancer have been
identified.66 RNA interference is beneficial in the modulation
of the aforementioned genes in anticancer therapy.67,68 The
discovery of RNAi and its application have a long history;
RNAi was first discovered in plants. Subsequently, scientists
attempted to exploit the potential of RNAi in gene editing. In
2006, Fire and Mello received the Nobel prize in medicine
because of their significant contribution in the field of RNAi.69
The extensive application of RNAi in anticancer therapy is not
accidental. The high specificity, effectiveness, minimal adverse
effects, and ease of preparation of RNAi has led to its use in
anticancer therapy.70
Small interfering RNA (siRNA) is a subcategory of small
RNA molecules with a length of 21−23 nucleotides.71 To
adequately performing its function, siRNA requires a complete
match with its target mRNA (mRNA).72 Furthermore, siRNA
suppresses the expression of its target gene at the post-
transcriptional level by mRNA degradation.73 Biogenesis of
siRNA commences via the degradation of long double-
stranded RNA in the cytoplasm via Dicer enzyme. For
activation, siRNA is embedded into an RNA-induced silencing
complex (RISC) to produce single-stranded RNA (ssRNA).
This ssRNA functions as an antisense guide for the RISC
complex. By binding to a complementary mRNA target, the
ssRNA causes degradation via Argonaute proteins.74,75
Application of first synthetic siRNA dated back to 2001
when Elbashir and colleagues used siRNA for gene editing in
mammalian cells.76 Other scientists followed by using siRNA
for gene silencing in anticancer therapy.77,78 Because of the
capability of siRNA in selective targeting, much attention has
been directed toward using siRNA in treatment of different
cancers, Examples include breast cancer,79 lung cancer,80 brain
tumors,81 thyroid cancer,82 and bladder cancer.83 Recent
publications have shed some light on using siRNA in
anticancer therapy. Oncogene factors participating in cancer
malignancy may be targeted via SiRNA. The remodeling and
spacing factor-1 (RSF-1) is an oncogene factor that is high
expressed in cancer cells. Up-regulation of RSF-1 enhances the
proliferation of cancer cells and causes resistance of cancer
cells to chemotherapy.84 The siRNA-mediated RSF-1 silencing
in cervical cancer cells is associated with their enhanced
sensitivity to radiotherapy. Down-regulation of RSF-1 by
siRNA increases the efficacy of radiotherapy via stimulation of
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apoptosis, DNA damage, and cell cycle arrest in cervical cancer
cells.85 Apart from RSF-1, glucose transporter-1 (GLUT-1) is
also responsible for resistance of cancer cells to radio-
therapy;86,87 siRNA-induced GLUT1 inhibition render cancer
cells more responsive to radiotherapy by induce their DNA
damage and apoptosis.88 These two studies illustrate that
siRNA is a potential strategy in enhancing the efficacy of
radiotherapy. Invasion and metastasis of cancer cells may be
regulated with the use of siRNA. Matrix metalloproteinase-2
(MMP-2) is a proteinase that enhances the migration of cancer
cells and promotes lymph node metastasis via the degradation
of type IV basement membrane collagen.89 The siRNA-
mediated Annexin A7 inhibition reduces proliferation and
invasion of cancer cells via down-regulation of MMP-2 and
proliferating cell nuclear antigen (PCNA).90 Ribonucleotide
reductase (RR) is a potential target in anticancer therapy
because of its role in DNA repair and replication via catalytic
reduction.91 Ribonucleotide reductase regulatory subunit M2
(RRM2), a protein-coding gene, is expressed during the late
G1/early S phase and participates in DNA repair.92 RRM2
induces chemoresistance of cancer cells because of its
capabililty in DNA repair.93 In ovarian cancer cells, silencing
of RRM2 via siRNA induces DNA damage and inhibits their
repair. This, in turn, increases the sensitivity of cancer cells to
cisplatin chemotherapy.94
The signaling networks responsible for proliferation, meta-
stasis, radioresistance and chemoresistance of cancer cells have
been reported in previous studies. Targeting molecular
pathways is important in suppressing the aggressive behavior
of cancer cells and in promoting their responses to chemo-
therapy and radiotherapy. However, siRNA suffers from off-
targeting and are easily degraded by enzymes. These
drawbacks may be circumvented by using nanosized vehicles.
Similar to the encapsulation of natural product cargoes,
encapsulation of siRNA by nanocarriers protect them against
degradation during blood circulation. Nanomaterials can also
provide targeted delivery of siRNA to the tumor site. Potential
nanocarriers for delivery of siRNA in anticancer therapy will be
reviewed in the next section.
Because different therapeutics employed for combination
cancer treatment have specific sites and mechanisms of action,
nanovehicle-mediated co-delivery strategies are essential for
maximizing the synergistic effects against tumor cells.14 In light
of this, functionalized vehicles with site specific delivery have
attracted substantial attention in precisely delivering multiple
therapeutic agents/RNA for improved synergistic effects
(Figure 1).
Although siRNAs are important in anticancer therapy, there
are a number of extracellular and intracellular barriers that
challenge their efficacy.71 Among these siRNA limitations, off-
targeting, their instability in blood circulation, inadvertent
stimulation of the host’s immune responses, as well as their
incapability to enter cells (cell uptake) are the most
important.95 With respect to off-targeting, it has been reported
that one-tenth of siRNAs affect unintended genes.78 In
addition, siRNAs triggers immunotoxicity by inducing
inflammation and enhancing the levels of cytokines.96
Synthetic siRNAs may impair RNAi machinery by interfering
with the function of microRNAs (miRs) and stimulating the
overexpression of specific proteins.97 The most critical
challenge of siRNAs is their hydrophilic and anionic features
that inhibit their penetration through hydrophobic cellular
membranes.98
To circumvent this issue, various delivery platforms have
been developed for siRNAs. To date, polymeric nanoparticles,
gold nanoparticles, iron oxide nanoparticles, silicon dioxide
nanoparticles, carbon nanotubes, lipid nanoparticles, liposomal
nanoparticles, hydrogel nanoparticles, and aptamers have been
developed for delivery of siRNAs.99 Recent literatures have
reported the usefulness of siRNA-delivery systems in
anticancer therapy. Dendrimers are a subcategory of polymeric
nanoparticles with three components, including a central core,
an internaldendritic structure and an external surface with the
functional surface group. Dendrimers are promising candidates
for the delivery of anticancer drugs.100 SiRNA can be loaded
into dendrimers for anticancer therapy. Dendrimers remark-
ably enhance the cellular uptake of siRNAs and their release
from endosomes. This causes more effective up-regulation or
down-regulation of their targets, resulting in decrease in cancer
Figure 1. Anticancer therapy using a site-specific co-delivery strategy. SiRNA and phytochemicals can be coloaded on nanoparticles for promoting
their efficacy in cancer therapy. Encapsulation of siRNA in nanoparticles protects against degradation. Nanoparticles enhance bioavailability of
natural products. Blood circulation time of siRNA and phytochemicals increases by nanoparticles. Various nanoparticles, such as micelles,
liposomes, dendrimers, and polymeric nanoparticles can provide targeted delivery of siRNA and phytochemicals at tumor site, leading to an
increase in their efficacy in apoptosis induction.
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malignancy.101 Selenium nanoparticles are beneficial in drug
and gene delivery. These nanoparticles overcome multidrug
resistance (MDR) because of their great biocompatibility and
high cellular uptake.102,103 Selenium nanoparticles not only
reduce adverse effects, they also enable maximum gene
silencing.104 Because of their low size (<100 nm), nano-
particles can infiltrate cellular impediments, such as the blood−
tumor barrier (BTB), the blood−brain barrier (BBB), and the
cell membrane.105,106 It has been reported that siRNA-loaded
nanocarriers can penetrate BBB via endocytosis and trans-
cytosis,107 resulting in more effective treatment of brain
tumors. Reduction in off-targeting and adverse effects,
enhancement of therapeutic capability and elevation of cellular
uptake are the benefits of using nanoparticles for siRNA
delivery.108−111 Table 1 summarizes the different nanocarriers
used for siRNA delivery in anticancer therapy.
■ NATURAL COMPOUNDS−siRNA CO-DELIVERY
Doxorubicin−siRNA Co-delivery. Doxorubicin (DOX)
belongs to the family of anthracyclines and is extensively
employed for the treatment of breast cancer, lung cancer,
ovarian cancer, cervical cancer, and thyroid cancer.121
Doxorubicin is derived from bacteria belonging to the genus
Streptomyces. It suppresses malignancy and proliferation of
cancer cells via inhibition of DNA topoisomerases, DNA
intercalation, and free radical generation.122 Despite its
excellent antitumor activity, DOX adversely affects normal
cells because of its off-targeting feature.123,124 This has resulted
in using nanoplatforms for the targeted delivery of DOX.125 In
addition, cancer cells are capable of developing resistance
against DOX chemotherapy.126 These two issues have resulted
in the use of combination therapy and nanoparticles. It has
been shown that siRNAs are helpful in reversing DOX
chemoresistance by targeting the genes involved in DOX
resistance.
A combination of DOX and siRNA has been used for
enhancing the antitumor activity of DOX against cancer cells.
Chemotherapeutic agents can reduce the malignancy of cancer
cells via EMT induction.127 Different molecular pathways
function as an upstream regulators of EMT in cancer. The Ras-
related C3 botulinum toxin substrate 1 (RAC1) is considered
as a key player in the regulation of invasion and metastasis of
cancer cells.128,129 The RAC1 attaches to nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase (NOX) and
increases the production of ROS.130 Formation of actin stress
fibers subsequently occurs by cytoskeleton reorganization.131
Down-regulation of RAC1 suppresses metastasis of cancer cells
via inhibition of EMT. The use of DOX and siRNA-RAC1
enhances the antitumor activity of DOX against breast cancer
cells via inhibition of EMT.132 The antitumor effect of DOX is
augmented by elevating its accumulation in cancer cells by
inhibition of P-gp activity via siRNA.133 The use of siRNA
enables negative targeting of oncogene factors, such as STAT3,
β-catenin, and Notch-1, which increases the antitumor activity
of DOX.134 Molecular pathways involved in proliferation and
growth of cancer cells, such as PI3K/Akt, may be targeted
using siRNA, resulting in an increase in cytotoxicity of DOX
against cancer cells.135 These studies are in support of the
value of collaborative antitumor therapy via DOX and
siRNA.136−138 Previous studies have examined the potential
of co-delivery of siRNA and DOX using nanoparticles in
anticancer therapy.139
Figure 2. Co-delivery of DOX−siRNA in anticancer therapy and affected molecular pathways. Nanovehicles facilitate the penetration of siRNA and
DOX through the cell membrane. SiRNA down-regulates molecular pathways that are responsible for cancer progression to promote antitumor
activity of DOX.
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The advent of nanotechnology facilitates simultaneous
chemotherapy and immunotherapy. Programmed death-ligand
1 (PD-L1) is the key element of the PD-1/PD-L1 axis that
induces apoptosis of T cells, inhibits their proliferation and
provides immune escape of cancer cells.140,141 Down-
regulation of PD-L1 is a potential strategy in the elimination
of cancer cells by enhancing the cytotoxicity of T cells against
tumor cells.142 The combination of DOX and siRNA-PD-L1 is
beneficial in anticancer therapy. Cancer cell membrane-coated
nanoparticles (CCMNPs) are capable of codelivering DOX
and siRNA−PD-L1. Improved cellular uptake of CCMNPs
enhances the internalization of PD-L1 and DOX, resulting in
concomitant chemotherapy and immunotherapy.143 Internal-
ization of DOX in cancer cells may be improved by targeting
transporters. The role of P-gp in exporting chemotherapeutic
agents out of the cell has previously been reported.144 Loading
siRNA−MDR1 on nanoparticles for co-delivery with DOX is
important for enhancing the antitumor activity of DOX.
Expression and activity of P-gp are reduced by down-regulation
of MDR1. This results in increased accumulation of DOX in
cancer cells to improve its antitumor activity.145
Surface modification of nanoparticles with receptors and
ligands can be made to enhance their targeted delivery. The
EphA10 demonstrates high expression in cancers and is
correlated with the progression and malignancy of cancer
cells.146 Surface modification of nanoparticles with EphA10−
antibody enhances their cellular uptake, leading to effective
inhibition of P-gp and cytotoxicity of DOX.147 Following the
design of nanoparticles that are capable of increasing
intracellular DOX uptake, the next step should be devoted to
developing strategies in reducing the viability and proliferation
of cancer cells to maximize the antitumor activity of DOX. In
this way, siRNA−Bcl-2- and DOX-loaded liposomes have been
designed. By down-regulation of the antiapototic factor Bcl-2,
the cancer cells undergo apoptosis and increase their sensitivity
to DOX-mediated cell death.148 Nanoparticles are valuable for
targeted delivery and enhanced cellular uptake of siRNA−Bcl-2
and DOX in anticancer therapy.149
Cytosolic Ca2+ is a vital signal transduction regulator that
has a variety of biological functions, such as modulation of cell
proliferation, tumorigenesis, and migration.150−152 The Ca2+
channels and pumps accounting for Ca2+ transportation are up-
regulated in different cancers.153−155 These pumps increase the
concentration of Ca2+ in the cells to activate Ca2+-related
pathways.156 Activation of Ca2+-related pathways induces drug
resistance.157 As a consequence, attention has been directed
toward inhibition of Ca2+ pumps, such as low-voltage activated
T-type Ca2+ channels in anticancer therapy.158−160 Encapsu-
lation of siRNA against T-type Ca2+ channels and DOX by
mesoporous silica nanoparticles reduces the activity of these
channels, resulting in inhibition of DOX resistance in breast
cancer cells.161 In addition to siRNA, other plant derived-
natural compounds may be loaded into nanoparticles. The co-
delivery of siRNA, quercetin and DOX suppresses proliferation
and malignancy of cancer cells by providing collaborative
antitumor therapy (Figure 2).162,163
The JNK-interacting protein 1 (JIP1) is an oncogene factor
involved in the development of resistance against DOX by
cancer cells. Down-regulation of JIP1 enhances the sensitivity
of DOX chemotherapy.164 Co-delivery of JIP1 and DOX by
cationic nanoliposomes inhibits the resistance of osteosarcoma
cells to chemotherapy via induction of apoptosis and
cytotoxicity.165 The erythropoietin-producing human hepato-
cellular receptor A2 (EphA2) undergoes up-regulation in
osteosarcoma cells. Loading of the histidine-tagged EphA2
receptor-specific peptide (YSA peptide) as a ligand of EphA2
into cationic nanoliposomes enhances the efficacy of delivery
of siRNA and DOX into cancer cells.165 In addition to
liposomes, graphene oxide may be used for DOX delivery.
Graphene oxide is an oxidative product of graphite. The
excellent biocompatibility and biodegradability of graphene
oxide have made it valuable for drug delivery.166−171 Co-
delivery of siRNA−VEGF and DOX using graphene oxide
enhances their cellular uptake and targeted delivery, resulting
in suppressing growth and metastasis of cancer cells.172
Apart from side effects, chemoresistance is a major problem
associated with DOX-related chemotherapy. Enhanced meta-
stasis is correlated with DOX resistance. EMT inhibition via
siRNA leads to DOX sensitivity. Furthermore, P-gp that
contributes to pumping out DOX from cancer cells and
triggering chemoresistance is inhibited by siRNA.
Encapsulants offer a platform for co-delivery of DOX and
siRNA to promote siRNA efficiency in gene silencing, and to
increase DOX accumulation in cancer cells. The advantage of
using siRNA is simultaneous chemotherapy and immunother-
apy. For instance, siRNA-PD-L1 can be applied for preventing
immune evasion of cancer cells to support the use of DOX in
chemotherapy. siRNA-Bcl-2 may be used to promote the
efficacy of DOX in apoptosis induction. To increase the
selective targeting capability of nanocarriers, surface mod-
ification of nanoparticles with receptors, such as EphA10 has
been adapted to promote their cellular uptake. Apart from
DOX and siRNA, other antitumor agents, such as quercetin,
can be loaded into nanoparticles to increase their efficacy
against cancer cells. However, one of the drawbacks is the large
particle size of nanoparticles. As shown in Table 2, most of
synthesized NPs have particle size that are more than 100 nm.
Future studies have to be focused on reducing the particle size
of nanocarriers to enhance cellular uptake. Table 2 summarizes
the DOX−siRNA co-delivery platforms used experimentally in
anticancer therapy.
Curcumin−siRNA Co-delivery. Curcumin is a naturally
occurring nutraceutical compound derived from Curcuma
longa.189 This compound is responsible for the yellow color
of turmeric and is responsible for the purported therapeutic
activities of Curcuma longa.190,191 Curcumin has a number of
pharmacological effects such as neuroprotective,192 cardiopro-
tective,193 hepatoprotective,194 antitumor,195,196 antioxidant,197
and anti-inflammatory effects.198 In terms of antitumor activity,
many studies have reported the efficacy of curcumin in
suppressing the proliferation, viability, and migration of cancer
cells via targeting molecular pathways and mechanisms, such as
apoptosis, autophagy, STAT3, Bcl-2, Bax, caspase, Wnt, and
Nrf2.199−203 Similar to other plant-derived natural compounds,
curcumin suffers from poor bioavailability.204 Loading
curcumin into nanoparticles has been reported to remarkably
enhance its antitumor activity.205 Curcumin has been used
with gene therapy to augment its antitumor activity.206,207
Because of curcumin’s poor bioavailabililty, studies have
focused on developing nanosized encapsulants for co-delivery
of curcumin and siRNAs. To date, four studies have evaluated
curcumin−siRNA co-delivery in anticancer therapy, which are
summarized below.
Polyamidoamine (PAMAM) dendrimers are promising
candidates in drug and gene delivery because of the high
density of surface groups, capability of sustained cargo release,
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spherical shape, low polydispersity, and water solubility.208,209
The hydrophobic interior of PAMAM dendrimers is ideal for
the encapsulation of hydrophobic compounds, while their
hydrophilic surface provides sites for attachment of siRNA.210
Both siRNA and curcumin can be codelivered by PAMAM
dendrimers into cancer cells. Anticancerous effect was achieved
by synergistic inhibition of Bcl-2 expression by the siRNA and
antitumor acivity of curcumin (Figure 3).211
The STAT3 signaling pathway is an oncogene factor that
enhances the proliferation and invasion of cancer cells.212,213
Down-regulation of STAT3 causes apoptosis of skin cancer
cells and inhibits their migration and growth.214,215 Because
curcumin targets the STAT3 signaling pathway in anticancer
therapy, co-delivery of curcumin and STAT3-targeting siRNA
can provide synergistic effects. In vitro and in vivo experiments
demonstrate that curcumin- and siRNA−STAT3-loaded
cationic liposomes are capable of suppress skin cancer
progression and malignancy via down-regulation of STAT3
and disruption of cancer growth.216 The efficacy of cationic
liposomes in the co-delivery of curcumin and siRNA-STAT3 in
therapy against skin cancer was also investigated in another
study. This combination remarkably suppressed skin cancer
proliferation, growth, and survival.217 Because STAT3 in an
oncogene for skin cancer (melanoma), silencing of STAT3
using siRNA interferes with cancer growth and invasion.
Delivery of curcumin also enhances the inhibitory impact of
STAT3 on melanoma cells. Nonviral vehicles, such as Au
nanoparticles, carbon nanotubes, and silica nanoparticles are
not biodegradable.218−220 Degradation of biodegradable
polymers, such as poly(lactic-co-glycolic acid) nanoparticles,
results in the production of acidic oligomers and creation of a
low pH environment that are toxic for cells.221 Zinc−curcumin
nanoparticles are free of the aforementioned drawbacks. Zinc
ions enhance the solubility of curcumin and increases it cellular
uptake. Zinc nanoparticles release drug in tumor sites in
response to pH. Because of its high cellular uptake, siRNA−
elF5A2 enters readily into cancer cells. Co-delivery of
curcumin and siRNA−elF5A2 inhibits proliferation and
malignancy of bladder cancer cells both in vitro and in vivo.
The combination induces apoptosis of the bladder cancer cells
via upregulation of Bax and down-regulation of Bcl-2 (Figures
2 and 4).222
One of the most well-known phytochemicals in anticancer
therapy is curcumin. Many cell culture and animal experiments
have been performed to evaluate its antitumor activity against
different types of cancer. The poor bioavailability of curcumin
may be resolved by coadministration with piperine derived
from black pepper or using nanoparticles that significantly
promote curcumin accumulation in cancer cells.223
Antitumor activity of curcumin may be improved by its
coapplication with siRNA. For instance, siRNAs can down-
regulate expression of Bcl-2, STAT3, and elF5A2 to interfere
with cancer cell proliferation. This paves the way for enhanced
antitumor activity of curcumin against cancer cells. A
combination of curcumin and siRNA, and their co-delivery
by nanoparticles can provide effective anticancer therapy. To
date, only a few studies have evaluated the efficiency of this
combination. Further studies should focus on the ability of
curcumin and siRNA in down-regulation of other signaling
networks, such as Nrf2, Wnt, c-Myc, and SOX in anticancer
therapy. Other nanocarriers, such as micelles, liposomes, and
carbon nanotubes can be designed for co-delivery of curcumin
Figure 3. Co-delivery of curcumin and siRNA in cancer therapy with focus on molecular signaling pathways. Down-regulation of Bcl-2, elF5A2, and
STAT3 by siRNA increases the antitumor activity of curcumin against cancer cells. Nanoparticles promote cellular accumulation of siRNA and
curcumin to enhance their antitumor potential.
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and siRNA. Table 3 represents curcumin−siRNA co-delivery
in anticancer therapy.
Taxane−siRNA Co-delivery. Docetaxel−siRNA Co-deliv-
ery. Docetaxel (DTX) is a semisynthetic taxane derived from
the needles of the European yew tree.224 This chemo-
therapeutic agent functions by inhibiting cell replication via
interfering with microtubule network and stimulation of cell
cycle arrest.225 The US FDA has approved the application of
docetaxel for the treatment of lung cancer,226 prostate
cancer,227 ovarian cancer,228 and breast cancer.229 Several
clinical trials have evaluated the efficacy of docetaxel in
anticancer therapy, and it is considered as an ideal candidate in
chemotherapy of cancer patients.230−232 Different pathways
and mechanisms contribute to the resistance of cancer cells in
docetaxel chemotherapy. Regulation of these molecular
pathways and mechanisms is important in the reversal of
docetaxel resistance. Modulation of miR expression, Nrf2, and
Klotho demonstrated promising results in inhibition of
docetaxel resistance.230,233,234 More importantly, genes may
be modulated by siRNA to improve the antitumor activity of
Figure 4. (A) Evaluation of antitumor potential of Zn(II)−Cur NP/siELF5A2 complex in a xenograft model. (B) Size of tumor treated with
different therapeutics is shown. (C) Tumor volume based on days post xenograft implantation with Zn(II)−Cur NPs, Zn(II)−Cur NPs/siNC, and
Zn(II)−Cur NPs/siEIF5A2 (20 mg of siEIF5A2 per injection, 50:1 mass ratio). (D) Mean tumor weights implanted with Zn(II)−Cur NPs,
Zn(II)−Cur NPs/siNC, and Zn(II)−Cur NPs/siEIF5A2. (E) Western blots of specimens using anti-EIF5A2 and anti-GAPDH antibodies. (F)
Western blots of the tissue specimens using anti-BCL-2, anti-BAX, and anti-GAPDH antibodies. Reproduced from ref 222 with permission from
Royal Society of Chemistry.
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Figure 5. (A) Schematic illustration of the fabrication and therapeutic mechanism of siRNA and DTX coloaded host−guest gold nanorods
(GNRs). (B) Temperature elevation, (C) infrared thermal images of 4T1 tumors upon laser irradiation at various power densities (200, 300, 400,
and 500 mW cm −2), (D) tumor growth curves, and (E) change of tumor weight after treated with GDTX/siRNA nanoparticles and 655 nm laser;
the black arrows indicated the time points for DTX/siRNA injection and laser irradiation. (F) Tumor photographs with different treatment.
Reproduced from ref 248 with permission from Wiley.
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docetaxel. Knockout of the oncogenes Notch1 and CIP2A by
siRNA enhances the efficacy of etoposide in eradication of
cancer cells.235,236 The antitumor activity of etoposide and
potential of siRNA in gene silencing may be promoted using
nanoplatforms. To date, different studies have evaluated the
efficacy of co-delivery of docetaxel and siRNA using nano-
particles.
The ERK-1 (p42-MAPK) and ERK-2 (p44-MAPK) kinases
can be induced by growth factors through Ras-Raf-dependent
pathways and are upregulated in prostate cancer cells.237
Suppressing the expression of these MAPL kinases for
elimination of prostate cancer cells.238,239 To optimize therapy
against prostate cancer, a combination of etoposide and
siRNA-MAPK has been experimental codelivered by polymeric
nanoparticles into cancer cells. The codelivered siRNA-MAPK
diminished the expression of ERK-1 and ERK-2 and
suppressed the proliferation and invasion of prostate cancer
cells, while the codelivered etoposide induced apoptosis and
cell cycle arrest via down-regulation of α-tubulin.240
Matrix metalloproteinase-9 (MMP-9) is involved in the
metastasis of cancer cells. This protease degrades the cell
membrane of cancer cells and enhances their mobility and
progression, resulting in poor prognosis.241,242 Because MMP-
9 increases the resistance of cancer cells to chemo-
therapy,243,244 it is a suitable target in anticancer therapy. A
potential strategy combining docetaxel and siRNA−MMP-9
has been used experimentally for the treatment of breast
cancer. The docetaxel- and siRNA−MMP-9-loaded polymeric
nanoparticles inhibit migration and viability of breast cancer
cells by down-regulation of MMP-9 (inhibition of metastasis)
and cellular uptake of docetaxel (apoptosis induction).245
Because MMP-9 induces epithelial-to-mesenchymal transition
via extracellular matrix degradation,246 it is rational to down-
regulate MMP-9 to control malignancy and sensitize the cancer
cells to chemotherapy.247 Breast cancer cells have been found
in the lung due to metastasis. Down-regulation of MMP-9
enhances the overall survival of patients with breast cancer.
Loading docetaxel and siRNA−p65 into nanoparticles
significantly suppresses lung metastasis of breast cancer cells
via inhibition of MMP-2 and Bcl-2, and stimulation of
apoptosis (Figure 5).248 These studies indicate that nanoplat-
forms are beneficial in co-delivery of etoposide and siRNAs to
enhance internalization of etoposide by promoting its
antitumor activity and suppressing the migration and
proliferation of cancer cells.249
Autophagy is a type II programmed cell death and plays a
pivotal role in the degradation of proteins and organelles, such
as the Golgi apparatus, mitochondria, and endoplasmic
reticulum.250 Autophagy is correlated with metabolic stress,
genomic damage and tumorigenesis.251 Autophagy is not only
involved in survival and progression of cancer cells, but can
increase the resistance of cancer cells to chemotherapy.252,253
For example, autophagy increases the resistance of cancer cells
to docetaxel chemotherapy.254,255 Consequently, regulation of
autophagy is important in cancer therapy. A combination of
docetaxel and siRNA−ATG7 has been used experimentally for
the treatment of breast cancer. ATG7 is an upstream inducer
of autophagy.256 Administration of docetaxel stimulates
autophagy and suppresses the proliferation and migration of
breast cancer cells. Co-delivery of siRNA-ATG7 and docetaxel
using micelles suppresses prosurvival autophagy in breast
Figure 6. Co-delivery of docetaxel−siRNA in treatment of cancer. Suppression of the proliferation and metastasis of cancer cells is provided using
siRNA-ATG7, p65, MMP-9, and MAPK. This results in increase in cytotoxicity of DTX docetaxel against cancer cells. Nanoparticles provide a
platform for co-delivery of docetaxel and siRNA in triggering chemosensitivity.
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cancer cells and improves the efficacy of docetaxel in the
stimulation of apoptosis.257
The surface of nanoparticles may be modified with receptors
to enhance the cellular uptake of siRNA- and docetaxel-loaded
nanoparticles. The low-density lipoprotein receptor-related
protein (LRP) receptor undergoes up-regulation in BBB and
glioblastoma cells.258−260 Angiopep-2 and tLyp-1 are ligands
that on bind to receptors on cancer cells and penetrate these
cells.261−264 Surface modification of liposomes with Angiopep-
2 and tLyp-1 has been performed to enhance their penetration
into glioblastoma cells, resulting to increase in the internal-
ization of docetaxel and siRNA−VEGF.265 Liposomes provide
an effective platform for coloading of siRNA and docetaxel.
This co-delivery remarkably reduced the proliferation and
viability of cancer cells via induction of apoptosis.266 Micelles
are another potential candidate for drug delivery. They are
capable of encapsulating chemotherapeutic agents to improve
their antitumor activity.267,268 The antitumor activity of
siRNA−Bcl-2- and docetaxel-loaded micelles against breast
cancer cells has been investigated in a recent study. The
micelles codelivered siRNA and docetaxel to the tumor site.
This targeted delivery significantly reduced the growth of
cancer cells via induction of apoptosis and down-regulation of
the antiapoptotic factor Bcl-2 (Figure 6).269
Similar to other antitumor agents, siRNA and nanoparticles
have been successful in promoting the inhibitory effect of
docetaxel against cancer cells. Proliferation (MAPK) and
metastasis (MMP-9) have been down-regulated by siRNA in
promoting antitumor activity of docetaxel. Nanocarriers such
as polymeric nanoparticles and micelles have been used for
siRNA and docetaxel co-delivery. Autophagy induction
following docetaxel chemotherapy functions as a pro-survival
factor. SiRNA−ATG7 inhibits autophagy in promoting the
antitumor activity of docetaxel against cancer cells. Nano-
particles are potentially useful in anticancer therapy because
they are capable of inducing autophagy270−273 and that
autophagy has both oncogene and onco-suppressor func-
tions.274−277 Table 4 summarizes currently published docetax-
el−siRNA co-delivery platforms in anticancer therapy.
Paclitaxel−siRNA Co-delivery. Paclitaxel (PTX) is the first
member of the taxane family that was approved by the FDA for
use in clinical trials.284 This chemotherapeutic agent is
exclusively applied in the treatment of malignancies such as
breast cancer,285 lung cancer,286 brain tumors,287 ovarian
cancer,288 and cervical cancer.289 Nevertheless, the resistance
of cancer cells to paclitaxel has resulted in unfavorable
outcomes in its clinical applications.290 Different factors are
responsible for the resistance of cancer cells to paclitaxel
chemotherapy, including drug transporters and miRs.291
Identification of these pathways and mechanisms, as well as
further targeting, are beneficial for the reversal of paclitaxel
resistance.292 For the treatment of lung cancer, siRNA−Beclin
inhibits prosurvival autophagy in lung cancer cells and
sensitizes the cells to paclitaxel chemotherapy. By down-
regulating Beclin/autophagy, the expression and activities of P-
gp and multidrug resistance protein 7 (ABCC10) are reduced.
This generates the conditions for enhanced intracellular
accumulation of paclitaxel to promote its potent antitumor
activity.293 Using a combination of siRNA−VEGF and
paclitaxel is also beneficial in anticancer therapy. The
siRNA−VEGF suppresses metastasis of cancer cells, as well
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while paclitaxel exerts its inhibitory effect on the growth and
viability of cancer cells.294
Stathmin 1 (STMN1) is an oncogene that promotes growth
and differentiation of cancer cells.295 Targeting STMN1 is
important in anticancer therapy. siRNA-mediated STMN1
down-regulation is correlated with enhanced sensitivity of
cancer cells to paclitaxel chemotherapy.296 These studies
support the use of paclitaxel and siRNA to promote the
antitumor activity of paclitaxel and to inhibit the resistance of
cancer cells to paclitaxel chemotherapy.297 Future research in
improving the antitumor activity of paclitaxel and siRNA
should be directed at the use of nanotechnology. Nanoplat-
forms can effectively encapsulate siRNA and paclitaxel,
protecting them against degradation and providing targeted
delivery to the tumorous sites.298 Studies that evaluated the
efficacy of nanoparticles in co-delivery of siRNA and paclitaxel
will be reviewed below.
Solid lipid nanoparticles are potential nanocarriers contain-
ing physiological and biocompatible lipids. These nanocarriers
have a size of 10−1000 nm and are capable of encapsulating
both hydrophilic and hydrophobic drugs.299,300 Biocompati-
bility, sustained release, and biodegradability are additional
beneficial characteristics of solid lipid nanoparticles.301 Co-
delivery of siRNA−Bcl-2 and paclitaxel has been used in
experimental therapy against cervical cancer. These nano-
carriers induced apoptosis in cancer cells and reduced their
viability and proliferation via down-regulation of Bcl-2 and
stimulation of paclitaxel-mediated apoptosis.302 Gold nano-
particles may also be used for the delivery of siRNA because of
their adjustable physicochemical features.303 Bifunctional
polyethylene glycol moieties on the gold nanoparticles enhance
targeted delivery and cellular internalization.304 These nano-
carriers are used for co-delivery of siRNA−NF-κB and
paclitaxel. Surface modification of gold nanoparticles with
anisamide enhances their cellular uptake by prostate cancer
cells. Anisamide acts as a ligand for up-regulation of sigma
receptors in prostate cancer cells.305,306 Co-delivery of siRNA−
NF-κB and paclitaxel via anisamide-modified gold nano-
particles effectively down-regulate NF-κB and enhanced
intracellular accumulation of paclitaxel in prostate cancer
cells. This resulted in halting the proliferation and invasion of
cancer cells.307 Similar to docetaxel, there have been intense
interest in targeting genes involved in the viability and survival
of cancer cells, to render the cells more conducive to paclitaxel
chemotherapy. For example, siRNA−survivin and paclitaxel
have been loaded into cationic liposomes for antiglioma
therapy. Surface modification of these liposomes by CD133
enhances their cellular uptake by cancer cells. Down-regulation
of survivin, induction of apoptosis, and inhibition of
proliferation result from the use of these cationic liposomes.308
Apart from inhibiting the proliferation and growth of cancer
cells, regulating the migration of cancer cells is also of interest
in anticancer therapy. This is because cancer cells with high
motility result in poor prognosis.309,310 Inhibition of cancer cell
metastasis controlling factors involved in angiogenesis. The co-
delivery of siRNA−VEGF and paclitaxel by micelles sup-
pressed the proliferation and invasion (siRNA−VEGF) of
cancer cells, improving the overall prognosis (Figure 7).311
Focal adhesion kinase (FAK) is a novel target in anticancer
therapy because its expression is up-regulated in different
cancers.312 Overexpression of FAK increases the resistance of
cancer cells to chemotherapy. Accordingly, modulation of FAK
Figure 7. Targeting molecular pathways in anticancer therapy using paclitaxel−siRNA-loaded nanoparticles. SiRNA−Beclin inhibits autophagy and
enhances the antitumor activity of paclitaxel. SiRNA−STMN1, VEGF, Bcl-2, FAK, survivin, and NF-κB sensitize cancer cells to paclitaxel
chemotherapy. The potential of siRNA and paclitaxel in anticancer therapy is boosted when they are loaded into nanoparticles.
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expression can provide new therapeutic venues in inhibiting
chemoresistance.313 Surface modification of nanoparticles with
hyaluronic acid (HA) enhances their penetration into cancer
cells because HA binds to CD44, which is highly expressed on
cancer cells.314,315 The HA-modified poly(lactic-co-glycolic
acid) nanoparticles are able to target ovarian cancer cells, and
have high cellular uptake because they target CD44 receptors.
The siRNA−FAK reduces the resistance of ovarian cancer cells
to chemotherapy and paclitaxel induces apoptosis in cancer
cells.316 Efflux transporters and Bcl-2 are the most common
targets used to render cancerous cells more susceptible to
paclitaxel chemotherapy. Efflux transports such as P-gp inhibit
intracellular accumulation of chemotherapeutic agents while
Bcl-2 suppresses apoptosis, thereby increasing the viability and
survival of cancer cells.317,318 Co-delivery of siRNA−Bcl-2,
siRNA−MDR1, and paclitaxel via poly(lactic-co-glycolic acid)
nanoparticles is associated with improvement in the antitumor
activity of paclitaxel, inhibition of growth and proliferation of
cancer cells, and increased accumulation of paclitaxel within
cancer cells.319 Paclitaxel resistance is gradually becoming an
increasing challenge in anticancer therapeutics. Overcoming
paclitaxel resistance requires designing a collaborative anti-
tumor therapy in which siRNA inhibits expression of genes
involved in paclitaxel resistance. Other hurdles include
eliminating the poor bioavailability of paclitaxel and enhancing
its targeted delivery. Nanoplatforms are able to release
paclitaxel at the tumor site and enhance its internal-
ization.320−330 Co-delivery of paclitaxel and siRNA has been
extensively investigated in anticancer therapy. Overall,
proliferation and metastasis are negatively affected by paclitaxel
and siRNA. Paclitaxel and siRNA impede angiogenesis via
VEGF down-regulation to disrupt cancer metastasis. Nano-
particles are used to promote siRNA in gene silencing and
paclitaxel internalization into cancer cells. Table 5 is a
summary of currently reported paclitaxel−siRNA co-delivery
platforms in anticancer therapy.
Etoposide−siRNA Co-delivery. Etoposide is a member of
epipodophyllotoxins that are capable of suppressing the activity
of DNA topoisomerase II.342 This chemotherapeutic agent
exerts its antitumor activity by inhibition of DNA topoisomer-
ase and subsequent induction of DNA damage and apoptotic
cell death.343,344 To date, etoposide has been applied in the
treatment of different cancers with excellent results achieved in
clinical trials.345−347 There is still a long way in improving the
antitumor activity of etoposide. Similar to other chemo-
therapeutic agents, cancer cells are capable of acquiring
resistance to etoposide chemotherapy.348,349 Studies have
looked at the use of combined etoposide and gene therapy
in the treatment of cancer. This regime demonstrated
satisfactory results in cancer therapy. The ABCB1 is a drug
transporter involved in imparting cancer cells with resistance to
chemotherapy. This is achieved by controlling efflux of
chemotherapeutic agents and reducing their accumulation in
cancer cells that results in chemoresistance.350 The siRNA−
ABCB1 effectively suppresses this transporter and enhances
etoposide accumulation in cancer cells, thereby decreasing the
viability and proliferation of cancer cells.351 In addition to
transporters, genes participating in the survival of cancer cells
may also be targeted. Silencing survivin gene using siRNA
remarkably decreases the viability of leukemia cancer cells and
Figure 8. Down-stream targets of etoposide−siRNA nanoparticles in anticancer therapy. Promotion of etoposide accumulation by nanoparticles
and down-regulation of ABCB1 by siRNA. This demonstrates how a combination of nanoparticles and siRNA promotes internalization of
etoposide into cancerous cells. Metastasis, angiogenesis, and proliferation are suppressed following co-delivery of siRNA and etoposide by
nanoparticles.
ACS Combinatorial Science pubs.acs.org/acscombsci Review
https://dx.doi.org/10.1021/acscombsci.0c00099
ACS Comb. Sci. 2020, 22, 669−700
683
induces their apoptosis.352 Another apoptotic factor is p53.
The oncoprotein inhibitory member of the ASPP family
(iASPP) functions as an upstream modulator of p53; iASPP
reduces the expression of p53 and renders cancer cells resistant
to apoptosis.353,354 Knock-down of iASPP by siRNA stimulates
the expression of p53 and make cancer cells susceptible to
etoposide-mediated apoptosis.355 Although the combination of
etoposide and siRNA is beneficial in cancer elimination,356
further progress has to be made to enhance the efficacy of
these agents. This may be achieved by using nanotechnology as
platforms for targeted delivery of etoposide and siRNA.
Small interfering RNA may be used to knockout the genes
involved in malignancy. Vascular endothelial growth factor
(VEGF) is an oncogene involved in enhancing tumor
neovascularization and is up-regulated in different types of
cancer.357,358 Because of the role of VEGF in promoting cancer
growth and viability, studies have been performed on the
inhibition of VEGF expression in anticancer therapy.359,360
The combination of siRNA−VEGF and etoposide appears to
be beneficial in the treatment of lung cancer. Multifunctional
nanoparticles have been used as platforms for coloading of
siRNA−VEGF and etoposide. The multifunctional nano-
particles are capable of codelivering siRNA−VEGF and
etoposide to tumor cells because of their excellent internal-
ization potential. The mild acidic pH of the tumor micro-
environment induces the release of siRNA−VEGF and
etoposide, providing targeted delivery. Effective co-delivery of
siRNA−VEGF and etoposide resulted in suppression of
angiogenesis and metastasis of lung cancer cells.361 Another
oncogene in lung cancer cells is the enhancer of zeste
homologue 2 (EZH2) belonging to the family of the Polycomb
Group (PcG) gene. This protein is overexpressed in lung
cancer,362 breast cancer,363 thyroid cancer,364 as well as in
brain tumors.365 Co-delivery of siRNA−EZH2 and etoposide
using multifunctional nanoparticles has been experimental used
for fighting lung cancer. In vitro and in vivo experiments
demonstrated that the multifunctional nanoparticles provide
targeted co-delivery of siRNA−EZH2 and etoposide, decreas-
ing the proliferation, and metastasis of lung cancer cells.366
Because etoposide is frequently used for anticancer therapy,
cancer cells may develop resistance to this chemotherapeutic
agent. There is a need to identify the molecular pathways
involved in the development of etoposide resistance. This will
facilitate the design of relevant siRNA and selection of
appropriate nanoparticles for targeted co-delivery of etoposide
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Figure 9. Targeting molecular signaling pathways in cancer therapy using resveratrol−siRNA-loaded nanoparticles. Apoptosis induction via
siRNA−RAD51 and HSP27 results in increase in the antitumor activity of resveratrol. Co-delivery of resveratrol and siRNA by nanoparticles
enhances their cellular uptake and antitumor potential.
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and siRNA (Figure 8).367 Table 6 represents etoposide−
siRNA co-delivery platforms in cancer therapy.
Resveratrol−siRNA Co-delivery. Resveratrol is a plant
derived-chemical compound belonging to the flavonoid
family.372 It has two distinct isoforms, trans-resveratrol and
cis-resveratrol.373 These isoforms can be transformed into one
another under certain circumstances. For example, exposure to
ultraviolet irradiation changes the cis isoform into the trans
form.374 Resveratrol is secreted by plants in response to biotic
and abiotic stresses.375 This naturally occurring polyphenol
provides defense against pathogens and is produced by edible
plants such as hops.376 Resveratrol possesses excellent
antioxidant, anti-inflammatory, antidiabetic, and neuroprotec-
tive activities.377−380 The antitumor activity of resveratrol has
provided a valuable option in anticancer therapy.381,382 Similar
to curcumin, the therapeutic effects of resveratrol are limited
by its poor bioavailability.383 The antitumor activity of
resveratrol may be accelerated by combining its use with
siRNA-based gene therapy.384 An example if the combination
of Res and siRNA−RAD51 in anticancer therapy. RAD51 is an
oncogene that is involved in cancer progression and chemo-
resistance.385 Silencing of RAD51 together with the admin-
istration of resveratrol effectively induce apoptosis in cancer
cells.386 Heat shock proteins (HSPs) are involved in
malignancy and HSP27 is one of these proteins. Over-
expression of HSP27 causes metastasis of cancer cells via
induction of epithelial−mesenchymal transition.387,388 A
combination of resveratrol and siRNA−HSP27 significantly
inhibited the proliferation and migration of glioblastoma cells
via down-regulation of HSP27 and activation of caspase-3,
which, in turn, causes apoptosis of the cancer cells.389
The use of nanoplatforms for co-delivery of Res and siRNA
enhances their antitumor activity. Over the past decades,
electrospun fibers have been considered ideal candidates for
drug delivery because of their potential in acting as platforms
for sustained drug release.390 Multilayered core−shell fibers
can be formed using multiaxial electrospinning. Drugs with
different release kinetics may be incorporated in different
compartments of the core−shell fibers.391 These electrospun
fibers for delivery of resveratrol to cancer cells. Resveratrol-
and siRNA-loaded electrospun fibers have been reported to
reduce the viability and proliferation of leukemia cells. This is
due to prolonged-release of resveratrol in 5 days and effective
delivery of resveratrol and siRNA to the tumor cells.370 Apart
from incorporating into a single nanoplatform, resveratrol and
siRNA may be loaded into two distinct nanocarriers. siRNA−
BCR-ABL liposomes and resveratrol-loaded electrospun fibers
have been prepared to reduce the viability and growth of
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Figure 10. Camptothecin and its co-delivery with siRNA in the treatment of cancer.
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leukemia cancer cells via sustained drug release.371 To date,
only two studies have investigated the co-delivery of resveratrol
and siRNA in anticancer therapy. Further studies should focus
on the development of other nanocarriers, such as polymeric
nanoparticles, solid lipid nanoparticles, niosomes, or carbon
dots for co-delivery of resveratrol and siRNA currently
reported (Figure 9). Table 7 represents resveratrol−siRNA
co-delivery platforms that have been used experimental in
anticancer therapy.
Camptothecin−siRNA Co-delivery. Adverse effects and off-
targeting of chemotherapeutic agents are two critical draw-
backs associated with their use.392 Camptothecin is a potential
chemotherapeutic agent capable of targeting DNA topoisomer-
ase I by suppressing its activities in DNA transcription,
replication, and chromosome condensation.393−395 Because the
antitumor activity of camptothecin is not affected by P-gp/
MDR1 resistance, it is a valuable option for anticancer
therapy.396 Nevertheless, modifications in the administration
of camptothecin should be performed to enhance its antitumor
activity. Camptothecin and siRNAs (siRNA−WRN and
siRNA−Egr-1) can be coadministered in anticancer therapy
to induce apoptosis of cancer cells, impair their proliferation,
and suppress chemoresistance.397,398 Nanocarriers may be used
to overcome the drawbacks associated with camptothecin (side
effects and off-targeting). Different nanoparticles have been
used for delivery of camptothecin in anticancer therapy.
Examples include polymeric nanoparticles, dendrimers,
micelles, nanofibers, carbon nanotube, and multifunctional
nanocarriers (Figure 10).173,399−405
Although camptothecin-loaded nanocarriers demonstrate
potential in reducing the survival and proliferation of cancer
cells, the antitumor activity of camptothecin may be further
optimized via co-delivery of siRNA. Polo-like kinase 1 (PLK1)
is a key member of the PLK family and has important
biological functions, such as bipolar arrangement of
centrosomes, spindle assembly checkpoint, and cytokine-
sis.406−408 Targeting of PLK-1 offers novel opportunities for
anticancer therapy because of its roles in chromosome
alignment and the cell cycle.409−411 The liposomes are capable
of release siRNA−PLK1 and camptothecin at tumor in a
sustained-release behavior. Release occurs in response to the
low pH of the tumor microenvironment. The siRNA−PLK-1
and camptothecin accumulate at the tumor site, the toxicity of
which causes apoptosis of the cancel cells.412 Apoptosis results
from the inhibitory effect of camptothecin on DNA top-
oisomerases and silencing of PLK1. Liposomes enhance the
accumulation of siRNA and camptothecin at the tumor sites.
Camptothecin is the least investigated antitumor agents that
we have discussed so far. Liposomes are the only nanocarriers
that have been applied for co-delivery of camptothecin and
siRNA against cancer. Other nanoparticles such as micelles,
polymeric nanoparticles, carbon nanotubes and metal nano-
particles may also be applied for co-delivery of siRNA and
camptothecin. Further studies will help in identifying the
efficacy of different types of nanocarriers in promoting the
antitumor activity of codelivered camptothecin and siRNA.
■ CONCLUSION AND REMARKS
The efficacy of nanocarriers for the co-delivery of siRNA and
natural products in the treatment of cancer was examined in
the present Review. Cancer cells develop resistance against
chemotherapeutic agents. Thus, ushering scientists to provide
new regimes and strategies in field of anticancer therapeutics.
Natural products are used in chemotherapy because of their
excellent antitumor activity and their capability to target
different molecular pathways. Two strategies may be
considered in the investigation of the antitumor activity of
natural products. The first strategy should focus on targeted
delivery of chemotherapeutic agents and enhancement in their
intracellular accumulation via the use of nanoparticles. The
poor bioavailability of many phytochemicals may be overcome
using nanoparticles. There are other barriers that limit the
antitumor activity of natural products. Nanosized encapsulants
derived from polymer and lipid organic nanomaterials, as well
as inorganic-based nanometals, have been designed to carry
siRNA and natural compounds. Encapsulants can inhibit
proliferation and of cancer cells via co-delivery of natural
compounds and siRNA. On one hand, this enhances the
effectiveness of siRNA in gene silencing. On the other hand,
the nanocarriers ameliorate the accumulation of natural
products in tumor cells. As an example, in treatment of brain
tumors, the BBB restricts the infiltration of antitumor agents
into the brain. Nanocarriers promote penetration of the
anticancer therapeutic agents through the BBB. Different
receptors, such as transferrin, can be incorporated on
nanoparticles for promoting their infiltration through the
BBB. The BTB is another impediment that limits the
penetration of antitumor agents into tumors. Nanoparticles
can facilitate the penetration through BTB and promote
internalization of antitumor agents. Hence, nanotechnology is
an inevitable part of anticancer therapy.
Uncontrolled metastasis and proliferation of cancer cells are
responsible chemoresistance. SiRNAs suppress cancer cell
metastasis (MMP-9) and proliferation (Bcl-2). They improve
the sensitivity of cancer cells to natural products with
anticancer properties. The off-targeting limitation of siRNA
may be improved via the use of nanotechnology. Nanovehicles
also protect siRNA and natural compounds from degradation
during blood circulation. Thus, nanocarriers, siRNA, and
natural products may be combined for effective treatment
against cancer. Nevertheless, these treatment regimes are still
at their infancy of development. Additional animal studies are
required to improve their efficacy prior to the implementation
of human clinical trials.
Some studies have examined the overexpression of specific
receptors on cancer cells, and have designed novel nano-
encapsulant for targeting those receptors via surface
modification. In addition to targeted delivery, the second
strategy may be directed toward targeting molecular pathways
and mechanisms involved in chemoresistance. These pathways
may be utilized for increasing the sensitivity of cancer cells to
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